

RESEARCH ARTICLE

Open Access

Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling

Jasna Bancovik^{1†}, Dayson F Moreira^{1†}, Daniel Carrasco², Jun Yao³, Dale Porter⁴, Ricardo Moura⁵, Anamaria Camargo⁵, Cibely C Fontes-Oliveira¹, Miguel G Malpartida¹, Silvia Carambula⁶, Edouard Vannier⁶, Bryan E Strauss⁷, Alda Wakamatsu⁸, Venancio AF Alves⁸, Angela F Logullo⁹, Fernando A Soares¹⁰, Kornelia Polyak¹¹ and José E Belizário^{1*}

Abstract

Background: We previously identified dermcidin (DCD), which encodes a growth and survival factor, as a gene amplified and overexpressed in a subset of breast tumors. Patients with DCD-positive breast cancer have worse prognostic features. We therefore searched for specific molecular signatures in DCD-positive breast carcinomas from patients and representative cell lines.

Methods: DCD expression was evaluated by qRT-PCR, immunohistochemical and immunoblot assays in normal and neoplastic tissues and cell lines. To investigate the role of DCD in breast tumorigenesis, we analyzed the consequences of its downregulation in human breast cancer cell lines using three specific shRNA lentiviral vectors. Genes up- and down-regulated by DCD were identified using Affymetrix microarray and analyzed by MetaCore Platform.

Results: We identified DCD splice variant (DCD-SV) that is co-expressed with DCD in primary invasive breast carcinomas and in other tissue types and cell lines. DCD expression in breast tumors from patients with clinical follow up data correlated with high histological grade, HER2 amplification and luminal subtype. We found that loss of DCD expression led to reduced cell proliferation, resistance to apoptosis, and suppressed tumorigenesis in immunodeficient mice. Network analysis of gene expression data revealed perturbed ERBB signaling following DCD shRNA expression including changes in the expression of ERBB receptors and their ligands.

Conclusions: These findings imply that DCD promotes breast tumorigenesis via modulation of ERBB signaling pathways. As ERBB signaling is also important for neural survival, HER2+ breast tumors may hijack DCD's neural survival-promoting functions to promote tumorigenesis.

Keywords: Breast cancer, Dermcidin, ERBB signaling, Oncogene, Apoptosis

Background

We previously described DCD as a candidate oncogene in breast cancer based on its copy number gain and overexpression in a subset of tumors [1]. Patients with DCD-positive breast cancer are more likely to have metastatic lymph nodes, larger tumors, and worse clinical outcome [1]. We also demonstrated that overexpression of DCD enhanced cell proliferation and resistance to oxidative stress-induced apoptosis in cell culture [1]. Furthermore, we showed that DCD encodes for a

secreted protein that binds to a candidate receptor present on the cell surface of breast cancer cells and neurons [1].

In normal human tissues DCD displays a restricted expression pattern with significant expression detected only in eccrine sweat glands of the skin [2] and in certain parts of the brain [1]. Overexpression of DCD was reported in multiple human tumor types including melanoma, cutaneous tumors, breast, prostate, pancreatic, and hepatocellular carcinomas [1,3-9]. The 11 kDa full-length DCD protein and proteolytic peptides derived from it have been proposed to have diverse biological functions, such as acting as a growth and survival factor in breast cancer [1] and in neural cells [10,11], displaying

* Correspondence: jebeliza@usp.br

†Equal contributors

¹Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900 São Paulo, SP, Brazil
Full list of author information is available at the end of the article

antibacterial activity [2,12,13], and inducing cancer-associated cachexia in animal models and in cancer patients [14,15]. In addition, a recent study demonstrated that DCD may function as a proteolytic enzyme which can cleave and activate the pro-MMP-9 matrix metalloproteinase and, thus, may also promote tumor cell invasion [16].

Despite the presumed importance of DCD in tumorigenesis and neurodegenerative diseases, the molecular mechanisms behind its many physiological and pathological functions, its receptor, and the signaling pathway activated by it remain obscure. The DCD gene appears to have evolved fairly recently during evolution, as no homologous genes could be identified beyond New World Monkeys based on Southern blot [1]. This apparent lack of DCD homologues in lower organisms made deciphering its biological function more difficult. Even in the human genome only two proteins show limited homology to DCD, and only one of these, lacritin (LACRT), has been characterized to some extent [17]. LACRT is closely linked to DCD at chromosome 12q13 and it is co-amplified and co-expressed with DCD in a subset of breast tumors [1]. Similar to DCD, lacritin is also a secreted survival factor and it was proposed to elicit its effects via activating a not-yet-identified G-protein coupled receptor(s) and calcium signaling [17–20]. However, it is unknown if DCD also functions via related signaling pathways.

To further investigate the function of DCD in breast cancer, here we describe the identification of a DCD splice variant (DCD-SV) and the consequences of down-regulating DCD expression in the MDA-MB-361 human HER2+ breast cancer cell line and upregulating DCD in the MCF-7 human HER2- breast cancer cell line and in the SK-BR-3 human HER2+ amplified cell line. Notably, we determined that DCD might elicit its oncogenic and pro-survival effects via modulation of ERBB signaling.

Methods

Cell lines and tissue specimens

Breast tumor specimens were obtained from Boston area hospitals and AC Camargo Cancer Center (São Paulo, SP, Brazil). Normal human skin and placenta were collected at Hospital São Paulo (São Paulo, SP, Brazil). The use of the human specimens was approved by the institutional review boards (IRB) of the Brigham and Women's and Massachusetts General Hospitals (Boston, MA, USA), Duke University Medical Center (Durham, NC, USA), the National Disease Research Interchange (Philadelphia, PA, USA) and AC Camargo Cancer Center (São Paulo, SP, Brazil). The need for informed consent was waived as the human specimens were deidentified. Breast cancer cell lines were previously described [1] and updated in Additional file 1: Table S1. For the generation of

derivatives of the MDA-MB-361 cell line expressing DCD shRNA, we designed shRNA against different regions of the DCD transcript and subcloned them into pLKO-puro lentiviral construct. Lentivirus generation and validation of the shRNA clones was performed as previously described [21]. For generation of the MCF-7-DCD and SK-BR-3-DCD human cell lines, the full length human DCD cDNA was cloned into pcDNA3.1+ expression vector at *Bam*H1 and *Eco*R1 restriction enzyme sites. Plasmids were transfected into cells using LipofectAMINE 2000 (Invitrogen) and selected in 200–600 µg/ml G418 (Invitrogen). Transfection was confirmed by PCR and Western blot analyses as previously described [22].

PCR, microarray, and network analyses

RNA preparation and RT-PCR analyses were conducted essentially as we described [1]. Gene expression profiling was performed by the Dana-Farber Microarray Core Facility using Affymetrix U133 Plus 2.0 chip following the manufacturer's protocols; data was analyzed by dChip software [23]. Microarray data was deposited into GEO, accession number # GSE57578, and is available to scientific community (Additional file 2). Gene expression levels were compared pair-wise between control pLKO and each of the three DCD shRNA derivatives. Genes that displayed statistically significantly different expression in all three pair-wise comparisons were selected for further analyses using the MetaCore platform essentially as previously described [24]. Details of network analyses are included in the Supplementary Data. Quantitative RT-PCR analyses were performed using SYBR Green RT-PCR kit (Invitrogen, Carlsbad, CA) according to manufacturer's instructions on Mx3005P[®] qPCR System (Agilent Technologies). REST[®] software was used for statistical analyses [25]. Expression data is expressed as means ± SD. Primer sequences used for PCR amplifications are available from the authors upon request.

Immunohistochemical, immunoprecipitation and immunoblotting analyses

Immunohistochemical analysis (IHC) of formalin fixed paraffin embedded cells and tissue samples was performed as previously described [1] using affinity-purified rabbit polyclonal raised against DCD synthetic peptide (RQAPKPRKQRSS) and DCD-SV synthetic peptide (RLVFGAPVNLTSIPLTSV), and commercially available antibodies to DCD as follow: G-81 mouse monoclonal [26], goat polyclonal (Santa Cruz Biotechnology, San Diego, CA) and rabbit polyclonal (Abgent Inc, San Diego, CA). The C-terminal peptides of human DCD and DCD-SV were used for target/specificity assay. Immunoblot analyses were performed as described [1]. For immunofluorescence, immunohistochemical and immunoprecipitation studies, the following mouse, human or rabbit primary and

secondary antibodies were used: EGFR (sc-03), pEGFR (tyr 1173, sc 12351) (Santa Cruz Biotechnology), EGFR and ErbB-2/HER2 (pharmDX), cytokeratin-5/6 and cytokeratin-18 (DakoCytomation), Trastuzumab/Herceptin (Genentech Inc, South Francisco, CA), pMAPK 38 (tyr 180, 182), pAKT (tyr 308) (Cell Signaling Technology), α -tubulin, β -actin (Sigma-Aldrich, St. Louis, MO), and FITC-labeled goat anti-mouse or rabbit (Santa Cruz Biotechnology and Cell Signaling). To evaluate the phosphorylation status of EGFR, the MDA-MD-361 or MCF-7 cell clones were treated with recombinant EGF (Sigma) for 15 min, and cultures washed twice ice-cold PBS and lysed in immunoprecipitation buffer as described [27]. Lysates were incubated with anti-pEGFR overnight at 4°C and next with protein A- and G-Sepharose for 2 h and then the immunocomplexes were pelleted by centrifugation. Western blotting was performed as described [1].

Cell proliferation and survival assays

For cell proliferation assays, cells were seeded at 4×10^3 cells per well in 24-well plates in DMEM with 1% FCS and treated with recombinant DCD at concentrations 1 to 1000 ng/ml. Cell proliferation was determined by incubating the cells for 3–5 days in the presence of 0.1 mM bromo-2'-deoxyuridine (Oncogene Research, Cambridge, MA) followed by detection using protocols provided by the manufacturer. For cellular survival assay, 1.2×10^3 cells in 96-well plates were incubated overnight and subsequently treated with different concentrations of H_2O_2 , staurosporine, and TNF- α with cyclohexamide for 16–18 hours. Cellular viability was determined using a tetrazolium salt assay (Sigma-Aldrich, St. Louis, MO). Each experimental condition was measured in quadruplicates and each experiment was performed at least three times. Results are expressed as mean \pm SEM.

Xenograft assays in immunodeficient mice

For xenograft assays, 6-week-old female BALB/c nude mice were subcutaneously injected in the flank with 200 μ l of matrigel (Becton-Dickson Biosciences, NJ) alone (control group) or mixed with 1×10^6 cells from MDA-MB-361 pLKO clone (pLKO group) or MDA-MB-361 DCD shRNA clone (IBC-I group). Five animals were used in each group. Body weight, tumor mass and overall status were monitored every two days throughout 45 days. Animal weight is expressed as mean \pm SD percentage of weight at injection. The mice were euthanized and organs and tumors were dissected, weighed and frozen in liquid nitrogen or fixed in 10% buffered formalin and embedded in paraffin. Xenograft experiments were repeated twice with essentially the same results. For *in vivo* therapy study, female nude mice (20–25 g) were subcutaneously injected

in the dorsal flank with $\sim 1 \times 10^6$ MDA-MB-361 parental cells diluted 1:1 in Matrigel. When tumor volumes reached 200–300 mm³, mice were randomly distributed into groups in order to test the different treatment. Animals in group 1 received intraperitoneal doses of trastuzumab (20 mg/kg), animal in group 2 received a mixture of goat polyclonal anti-DCD antibodies (1 mg/Kg), named N-20, A-20 and S-19 (Santa Cruz Biotech); and animal in group 3 their combination one a week for a five weeks. Tumors were measured with a caliper every week, and volume calculated by the formula: tumor volume = (width)² \times length \times 0.5. The body weight changes and performance status were monitored daily for 5 weeks. All animal experiments were performed according to a protocol approved by the Animal Care and Use Committee of the Institute of Biomedical Sciences, University of São Paulo.


Statistical analyses

Results are expressed as mean \pm SD. Data were analyzed by the Student's paired t-test, one-way (or two-way) ANOVA and Fisher's exact test as appropriate, using Prism software. For the mouse xenograft experiments, three groups of animals were compared using the exact Wilcoxon rank sum test.

Results

Expression of DCD and DCD-SV in normal and neoplastic tissues

While analyzing the expression of DCD by RT-PCR in various normal and neoplastic tissues and cell lines, we identified a larger transcript co-expressed with DCD. The transcript contains a different fifth exon as a result of alternative splicing (Figure 1A), thus, we designated it DCD-SV (for DCD splice variant). This 526 bp DCD-SV encodes a 12.1 kDa protein with a different C-terminus missing the hydrophobic coiled-coil structure (amino acids 80–103) thought to be essential for the antibacterial function of DCD [2]. The expression of DCD and DCD-SV correlated well in most tissue samples and cell lines analyzed, although the relative levels of the two transcripts demonstrated some variability (Figure 1A). To define relative DCD and DCD-SV expression levels more precisely, we performed quantitative RT-PCR analysis of various human tissue samples and cell lines. Among normal tissues, placenta expressed almost only DCD-SV, whereas in normal breast both transcripts were detected at a 2:1 ratio and cell lines displayed variable DCD and DCD-SV expression levels (data not shown). Another group also identified a short truncated (DCD-SV-1) and a larger (DCD-SV-2) form of DCD in human placental tissue [19]. DCD-SV-1 is expressed in villous parenchyma whereas the larger DCD-SV-2 isoform, which is similar to the DCD-SV sequence identified in



our study, is expressed preferentially in reflected membrane [16].

We performed IHC using different antibodies and routinely detected the expression of DCD and DCD-SV in epithelial cells of human eccrine sweat glands (used as control) and luminal side of secretory ducts (Figure 1B). The reactivity was not present in normal mammary epithelial cells, and reliable staining was present in membrane and weaker in cytoplasm of tumor cells (Figure 1C). Next, we examined ~600 samples of primary and invasive carcinomas spotted in two tissue microarrays slides. The patient cohort was previously clinic-pathological evaluated and the tumors classified as negative or positive for estrogen and progesterone receptors and EGFR and HER2 receptors [28]. The Nottingham system was used for assessment of histologic grade of each tumor [28]. A group of 26 samples with consistent DCD immunoreactivity in <50% or >50% of tumor cells was classified into subgroups according to their clinical and pathological features. Statistically significant associations ($p < 0.05$) were found between DCD reactivity >50% and the subgroups with either high histological grade or with HER2 score 3 (Table 1.A). No relationship with overall survival was found. These results are in line with the findings of our previous study analyzing a smaller cohort [1].

Table 1 Association of DCD expression and Breast Cancer Biomarkers**A. Association between the clinical-pathological features and molecular markers in DCD-positive breast cancer patient samples**

Characteristics	Invasive Breast Carcinoma, n = 26		
Median age, years range	56 (37–79)		
DCD expression	<50%	>50%	
	no. (%)	no. (%)	P-value
Nodal status			
Negative, n = 9	7 (77.8)	2 (22.2)	0,11
Positive, n = 17	7 (41.1)	10 (58.9)	
Histological Grade			
Intermediate, n = 10	7 (70)	3 (30)	0,008
High, n = 16	2 (12.5)	14 (87.5)	
Estrogen Receptor			
Negative, n = 15	6 (40)	9 (60)	0,13
Positive, n = 11	8 (72.7)	3 (27.3)	
Progesterone Receptor			
Negative, n = 16	6 (37.5)	10 (62.5)	0,22
Positive, n = 10	7 (70)	3 (30)	
ERBB2			
Score 0–2, n = 14	14 (100)	0	0,001
Score 3, n = 12	0	12 (100)	

B. Association between DCD and ERBBs mRNA expression in 55 breast cancer cell lines

	DCD expression (RMA,log2)		P-value
	<4	≥4	
	no. (%)	no. (%)	
ERBB2			
<8, n = 25	13 (23.6)	12 (21.8)	0,047
≥8, n = 30	7 (12.7)	23 (41.8)	
ERBB3			
<9, n = 21	12 (21.8)	9 (16.3)	0,044
≥9, n = 34	9 (16.3)	25 (45.4)	
ERBB4			
<4, n = 21	10 (18.1)	11 (20)	0,391
≥4, n = 34	11 f	23 (41.8)	
EGFR			
<7, n = 40	17 (30.9)	23 (41.8)	0,795
≥7, n = 15	5 (0.05)	10 (14.5)	

P = Statistical significance by Fisher's exact.

RMA = robust multiarray average.

To further confirm the association of ERBBs and DCD expression, we compiled freely available microarray data sets of 55 human breast cancer cell lines obtained from Cancer Cell Line Encyclopedia (<http://www.broadinstitute.org/ccle>). The list is described in Additional file 1: Table S1 and has representative models for the different subtypes of


the disease [29]. The association analyses were done across the subgroups classified as higher or lower based on whether the value was below or above the median of RMA (robust multiarray average) normalized expression value for the DCD and ERBB genes obtained in CCLE. Again, we found statistically significant association ($p < 0.05$) between DCD expression (RMA ≥ 4) with HER2 (RMA ≥ 8) and also with HER3 (RMA ≥ 9) expression (Table 1.B, Additional file 1: Table S1). As expected, in these groups are cell lines classified in the HER2 and luminal subtype, in which HER2 gene is amplified or superexpressed [29] and (Additional file 1: Table S1).

Consequences of DCD downregulation

To assess the function of DCD in breast cancer cells with high endogenous expression, we generated derivatives of the MDA-MB-361 human breast cancer cell line expressing three different shRNAs against DCD (IBC-I, IBC-II, and IBC-III) using pLKO plasmid-derived lentiviruses. Efficient downregulation of DCD mRNA and protein was confirmed by multiple assays including RT-PCR analyses (2C), immuno-cytochemistry (2A), and immuno-blotting (Figure 2D). Cells expressing DCD shRNAs had significantly reduced colony-forming ability (Figure 2B).

To evaluate if down-regulation of DCD affects cellular resistance to apoptosis, we exposed the cells to various doses of cytotoxic agents and found that their cellular resistance to H_2O_2 (Figure 2E), staurosporine (Figure 2F), and TNF- α at 200 ng/ml (Figure 2G) were significantly reduced. These results are in agreement with prior studies describing higher apoptosis resistance of cancer cells overexpressing DCD [1,6,7,9].

Next, we analyzed the effect of DCD downregulation on tumorigenesis by performing xenograft assays in immunodeficient mice. Mice inoculated with MDA-MB-361 cells expressing IBC-I shRNA developed smaller tumors compared to control pLKO cells (Figure 3A). The overall weight of various organs of mice inoculated with tumor cells was significantly reduced compared to animals without tumor, but no difference in body weight was observed between control and DCD shRNA expressing cells, and we did not observe cachexia in any of the experiments (Figure 3C,E). However, we observed a significant difference in tumor mass between control pLKO and IBC-I groups, which could explain the more pronounced weight losses of carcass, gastrocnemius, and soleus skeletal muscles in these mice (Figure 3E). Macroscopic local invasion or metastasis was not observed in any of the animals analyzed (data not shown). Immunohistochemical analysis confirmed decreased DCD protein levels in DCD shRNA expressing compared to control xenografts (Figure 3D). Additionally, we observed increased expression of CK-18 in DCD shRNA expressing xenografts implying more luminal




phenotype that could contribute to decreased tumor growth (Figure 3D).

Signaling pathways modulated by DCD

To investigate the mechanisms underlying the growth and survival-promoting effects of DCD in MDA-MB-361 breast cancer cells, we analyzed the global gene expression profiles of control pLKO and DCD shRNA expressing cells (Figure 4A, Additional file 3: Table S3). Genes were identified as differentially expressed if their expression showed at least three-fold difference in each of the three pair-wise comparisons. Using these criteria we identified 208 up and 27 down-regulated genes (Additional file 3: Table S3). Down-regulation of DCD resulted in decreased levels of several genes that regulate oxidative stress, hypoxia, and angiogenesis including disulfide isomerase-associated 3, 4 and 6 (PDIA), stress 70 kDa protein chaperone (STCH), heat shock 70 kDa protein 5 (GRP78), hypoxia-inducible gene 2 protein (HIG2), VEGF-A, and VEGF-B. The c-MYC transcription factor, which controls the expression of numerous genes involved in metabolism, protein synthesis, and cell proliferation was also down-regulated in DCD shRNA expressing cells.

Several genes regulating cell survival and death also showed altered expression in DCD shRNA expressing cells including protein phosphatase 3, the catalytic subunit of calcineurin A (PPP3CA), calcium/calmodulin-dependent protein kinase II delta (CAMK2D), thioredoxin-interacting protein (TXNIP), and cyclin-dependent kinase 6 (CDK-6). Calcineurin is a calcium and calmodulin-regulated protein phosphatase that acts as a molecular integrator of specific calcium signals. TXNIP is an inhibitor of thioredoxin, a central regulator of redox states [30]. Thus, cells overexpressing DCD may display increased resistance to oxidative stress-induced apoptosis due to their higher anti-oxidant activity potentially because thioredoxin is relieved of inhibition by TXNIP. Therefore, inhibiting DCD activity by antibodies or small molecules may increase tumor cell susceptibility to radiation and chemotherapy.

Systematic functional analysis of the differentially expressed genes using GEO revealed significant enrichment for genes with metabolic function among the 208 down-regulated genes, whereas among the 27 up-regulated genes were enriched in signal transduction pathways (Figure 4B). More detailed analysis of




signaling networks and pathway using the Metacore software [24] predicted higher connectivity among the genes within the EGFR signaling canonical pathway. Betacellulin, amphiregulin, EGFR and c-Myc expression levels decreased in each of the three different DCD shRNA expressing cell pools compared to control pLKO (Figure 4C, Additional file 4: Excel Spreadsheet 1, Additional file 5).

To experimentally validate these predictions of network analysis studies, we analyzed the expression levels of all ERBB family members by real time PCR in control and DCD shRNA expressing cells (Figure 5A,B). These analyses indicated that the expression levels for EGFR, ERBB2, and ERBB3, and their ligands BTC, EGF, TGF- α , AREG, HB-EGF, NGR1, and NGR4 were down-regulated, whereas the ERBB4 and ligands EREG and NGR2 were up-regulated in cells expressing DCD shRNAs. The reduction of EGFR protein levels was confirmed by immunohistochemical analysis of xenografts derived from DCD shRNA expressing cells (Additional file 6). To analyze signaling changes downstream of ERBB receptors, we

analyzed the phosphorylation status of EGFR, Akt and p42/44 MAPK in control and DCD shRNA expressing MDA-MB-361 cells untreated or treated with EGF 10 ng/ml. The phosphorylation of EGFR, Akt, and MAPK proteins increased in control pLKO cells but was low or no detectable in IBC-I cells (Figure 5H).

Interestingly, ERBB4 promotes differentiation in mammary epithelial cells [31,32] and it is associated with better prognosis in breast cancer patients [33,34]. ERBB4 may execute its differentiation-inducing function by dimerizing with other ERBB family members and decreasing the levels of more oncogenic ERBB heterodimers such as ERBB3/ERBB2 [35]. Correlating with this, MDA-MB-361 breast cancer cells expressing DCD shRNA displayed a more differentiated luminal epithelial cell phenotype compared to control cells (Figure 2A). The combined regulation of c-MYC, ERBBs, and several other signal pathways by DCD may play a role in this process. Thus, an intriguing hypothesis based on our data is that the physiologic function of DCD is to

and components of their signaling pathways (Figure 6). DCD overexpression increased colony formation and survival (Figure 6C,D) as well as xenograft growth in immunodeficient mice (data not shown). Similar observation was described previously [36]. The constitutive autocrine expression of DCD significantly increased the mRNA levels of EGFR, HER2/ErbB2, AREG, EGF, HB-EGF, NRG3, and NRG4 (Figure 6E,F). Following EGF stimulation, DCD-expressing MCF-7 cells displayed more pronounced phosphorylation of EGFR, Akt, and MAPK proteins compared to MCF-7 pCDNA cells (Figure 6G). Next, we demonstrated that the overexpression of DCD



gene in SK-BR-3 cells increase the proliferation of this HER2-amplified cell line as well as tumor growth when the cells were implanted in the mammary fat pads of female immunodeficient mice (Additional file 7: Figure S3). Thus, the pattern of changes observed in these two DCD overexpressing cells are the opposite of those found in MDA-MB-361 cells expressing DCD shRNAs strengthening the link between DCD and ERBB signaling.

To demonstrate that the observed effects were due to the extracellular actions of DCD, we analyzed the proliferation of MDA-MB-361 cells treated with 1–100 nM of highly purified recombinant human DCD (rhDCD) (Figure 5C). Similar to our prior findings [1], recombinant DCD enhanced cellular proliferation at 0.1–1 nM

but not at 10 and 100 nM. Similar bell-shaped dose-response curves have been observed in experiments that established Y-P30, a DCD-derived peptide, as a neural survival peptide [1,10,11], lacritin, a homolog to DCD [19] and other well-known mitogenic factors including sonic hedgehog, VEGF, FGF, and PDGF. More importantly, real time RT-PCR analyses of treated cells confirmed the up-regulation of EGFR, c-MYC, EGF, HB-EGF, and NRG3 (Figure 5D,E,F), whereas the expression of HER-2, –3 and –4 receptors and ligands AREG, BTC, TGF- α , and NRG4 did not change significantly (Figure 5F,G). Finally, we tested the efficacy of trastuzumab, a humanized polyclonal antibody against HER2, and goat polyclonal antibodies against DCD for the treatment




Figure 6 Characterization of MCF-7 cells stably expressing DCD. Quantitative RT-PCR (A) and western blot (B) analysis confirming the expression of DCD mRNA and protein in MCF-7-DCD cells. DCD transcript levels were normalized to that of HPRT using REST software and the expression level in MCF-7 pcDNA control was designated as 1. C, Quantitative analysis of colony numbers (>25 cells/colony) two weeks after plating of the cells. D, Cellular survival of control and DCD overexpressing MCF-7 cells treated with H₂O₂, at indicated concentration, for 16 hrs. Cell survival rates were estimated by MTT assay. Y-axis indicates % surviving cells as percentage of untreated control. Results are given as means \pm SD of three experiments. * $p < 0.01$ and ** $p < 0.001$ by Student t test. Quantitative RT-PCR analyses showing the fold-increases in the mRNA expression of ligands (E) and the receptors (F) of ERBB family in DCD expressing MCF-7 cells compared to control. Y-axis indicates mean \pm SD mRNA levels (normalized to HPRT) relative to controls. G, Effects of EGF treatment on the phosphorylation of EGFR and downstream signaling proteins p38-MAPK and pAkt in MCF-7 control and DCD-expressing cells following the treatment with EGF 10 ng/ml for 15 min.

of parental MDA-MB-361 cells *in vitro* and *in vivo* (Figure 7A,B). The results demonstrated that individually or the combination of anti-DCD antibodies and trastuzumab caused a significant reduction of the number of cell colonies in cell culture as well as the tumor growth as

xenograft in immunodeficient mice. These results confirm our hypothesis that DCD autocrinally produced by MDA-MB-361 cells may be acting in concert with the ligands of HER/ErbB receptor family to stimulate the growth and proliferation of breast cancer cells.




Figure 7 Enhanced effect of anti-DCD rabbit polyclonal antibodies and trastuzumab combination on growth and tumor formation of MDA-MB-361 cells *in vitro* and *in vivo*. **A**, Quantitative analysis of colony numbers observed 72 hours after inoculation of MDA-MB-361 cells in 96-well plates in the presence of 10% BFS (black column 1) or in the presence of 1% BFS plus non-specific antibodies (white column 1), or 1% BFS in the presence of non-specific antibody (black column 2, 3 and 4) or presence of the antibodies trastuzumab (20 mg/kg), a mixture of goat polyclonal anti-DCD antibodies or their mixture at final concentration of 100 µg/ml. Colonies numbers with ≥ 5 cells/colony were counted manually in at least 10 fields. Results are given as means \pm SD of three experiments and statistical difference ($p < 0,05$) were determined by Student *t* test. **B**, Fold-increase in the volume of MDA-MB-361 xenograft tumors growing in mice (4–5 animal in each group) untreated or treated with weekly i.p. doses of trastuzumab (20 mg/kg), a mixture of goat polyclonal anti-DCD antibodies (1 mg/kg), named N-20, A-20 and S-19 or their combination for a five weeks. Statistical difference ($p < 0,05$) were determined by One-way ANOVA with Turkey's pairwise comparisons.

Discussion

Here, we describe for the first time the co-expression of DCD and DCD-SV in normal skin tissue and breast cancer cell lines using validated and novel specific antibodies against different portions of these proteins. The DCD splice variant is identical in its nucleotide sequence to a larger (DCD-SV-2) form of DCD identified in human placental tissue as described [37]. Although we found an association of DCD with either high histological grade or with HER2 positive samples (score 3), we did not find a significant relationship between tumor samples having DCD reactivity and overall survival in this small cohort of 26 breast cancer patients. These results are in line with our previous studies [1,22,38].

There are few studies published in the literature that report possible molecular mechanism(s) by which DCD native protein and DCD-generated peptides exert their function as growth and survival factors and antibiotic peptides [6–13]. We believe that the binding to low and high affinity membrane receptors [1] would directly or indirectly promote the integration of network signaling pathways leading ultimately to

EGFR phosphorylation and activation of p38 MAPK and Akt (Figures 5 and 6). A recent study has described the crystal and atomic structure of DCD-1 L antibiotic peptide and detailed a mechanism by which individual peptides undergo oligomerization and assembly into a channel structure with ion conductivity properties across a biomimetic membrane [37]. It is not known if this putative channel is formed in mammalian membranes nor if it influences the growth rate of malignant cells.

Human breast cancer cells selected for resistance to trastuzumab *in vivo* overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network [27,35,39]. Our experiments in Figure 7 provide further evidence for parallel pathways and their possible mediators, for example, DCD. Finally, it is important to mention a recent study published by Wilhelm and colleagues [40] confirming the biological role of DCD as biomarker for cellular resistance of various tumor cells to the EGFR/ErbB1 tyrosine kinase inhibitors erlotinib and lapatinib.

Conclusions

Using gain-of-function and loss-of-function approaches we confirmed that DCD acts as a growth and survival-promoting factor in breast cancer. Furthermore, we demonstrated that these effects are due to the modulation of ERBB receptor signaling by DCD. In agreement with this, here and in a previous study [1], we found that DCD-expressing breast tumors are frequently HER2+. Our data also imply that DCD-expressing HER2+ tumors may be more likely to be resistant to HER2-targeted therapies; a hypothesis that worth investigating in future studies.

Additional files

Additional file 1: Table S1. ER/PR/ERBBs/DCD status, source, clinical and pathological features of the breast cancer cell lines. **Figure S1.** The average of RMA (robust multiarray average) normalized expression values for DCD, HER2, HER3, HER4 and EGFR in 55 breast cancer cell lines.

Additional file 2: GEO deposit GSE57578 of microarray data.

Additional file 3: Table S2. Microarray gene expression data for MDA-MB-361 control pLKO and DCD shRNA expressing subclones.

Additional file 4: Table S3. Bioinformatic analysis of signaling networks and pathways using MetaCore Software.

Additional file 5: Table S4. Legend to symbols and objects on Figure 4B.

Additional file 6: Figure S2. Representative immunohistochemical (IHC) analysis of EGFR, HER-2/ErB-2 and HER-4/ErB4 in xenografts derived from control and DCD shRNA expressing MDA-MB-361 cells.

Additional file 7: Figure S3. Characterization of SK-BR-3 stably expressing DCD gene and tumor growth as xenograft in immunodeficient mice.

Abbreviations

EGF: Epidermal growth factor receptor; EGFR: Epidermal growth factor receptor; HER2: Human epidermal growth factor receptor 2; HER3: Human epidermal growth factor receptor 3; RT-PCR: Reverse transcriptase polymerase chain reaction; qPCR: Quantitative PCR; pMAPK 38: Phosphorylated p38 mitogen-activated protein kinase 38; DMEM: Dulbecco's modified Eagle's medium; FCS: Fetal calf serum; TNF- α : Tumor necrosis factor- α ; SEM: The standard error of the mean; SD: The standard deviation; ANOVA: Analysis of variance; shRNA: Short hairpin RNA; VEGF: Vascular endothelial growth factor; BTC: Betacellulin; TGF- α : Transforming growth factor- α ; AREG: Amphiregulin; HB-EGF: Heparin-binding EGF-like growth factor; NGR: Neuregulin; GDF-15: Growth differentiation factor 15; Akt: Protein Kinase B (PKB).

Competing interests

KP receives research support from and is a consultant to Novartis Pharmaceuticals, Inc.

Authors' contributions

JEB and KP conceived and designed experiments. JB, DM, CCFO, MGM, SFC, RM, AC, SFC and EV performed real time PCR assays, cellular and biochemical experiments in breast cancer cell lines and analyzed data. DM and JEB performed xenograft tumor studies and analyzed the data. JY, DEC and carried PCRs assays, lentivirus cloning, gene expression profiling and dChip analysis. DP, AQ, VAFA, AFL and FAS carried out the tissue microarrays and immunohistochemistry assays and analyzed data. BES produced lentiviral particles. All authors read and approved the final version of the manuscript.

Authors' information

Jasna Bankovic and Dayson F Moreira are the co-first authors.

Acknowledgments

We are indebted to Akihiko Kimura for providing the G-81 anti-DCD antibody and Genentech Inc. for providing Herceptin antibody (OR-208654). We thank Dr Maria M Brentani, University of Sao Paulo School of Medicine, and Dr Victor Piana Andrade, AC Camargo Cancer Center for their help in TMA experiments and Ricardo Garcia and Carla Pietro for their help in SK-BR-3 cells experiments and fruitful discussions. This work was funded by FAPESP (Fundação de Amparo a Pesquisa do Estado de São Paulo) grant 2001/01000-7 and 2005/56909-0 (JEB), FAPESP fellowships (MGM, COF, and DFM), NIH (DP), and by Novartis (KP).

Author details

¹Department of Pharmacology, Institute of Biomedical Sciences - University of São Paulo, Av Lineu Prestes 1524, 05508-900 São Paulo, SP, Brazil. ²Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute - Harvard Medical School, 450 Brookline Ave. D740C, Boston, MA 02215, USA. ³Department of Neuro-Oncology Research, Division of Cancer Medicine, University of Texas - MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ⁴Oncology Disease Area and Developmental and Molecular Pathways Group, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA. ⁵Ludwig Institute for Cancer Research- Hospital Sírio-Libanês, Rua Peixoto Gomide, 316, 7th floor, 01409-000 São Paulo, SP, Brazil. ⁶Division of Geographic Medicine & Infectious Diseases, Tufts Medical Center, 25 Harvard Street - Tupper 729, Boston, MA 02111, USA. ⁷The Cancer Institute of São Paulo, Av. Dr. Arnaldo, 251, 8th floor, 01246-000 São Paulo, SP, Brazil. ⁸Department of Pathology - School of Medicine, University of São Paulo, Avenida Dr Enéas de Carvalho Aguiar, 155 - 10th floor, 05403-000 São Paulo, SP, Brazil. ⁹Department of Pathology - Paulista School of Medicine, Federal University of São Paulo, Rua Sena Madureira, 1500, 04021-001 São Paulo, SP, Brazil. ¹⁰Department of Pathology - AC Camargo Cancer Center, Rua Professor Antônio Prudente, 211, 01509-010 São Paulo, SP, Brazil. ¹¹Department of Medical Oncology, Dana-Farber Cancer Institute - Harvard Medical School, 450 Brookline Ave. D740C, Boston, MA 02215, USA.

Received: 3 June 2014 Accepted: 14 January 2015

Published online: 19 February 2015

References

- Porter D, Weremowicz S, Chin K, Seth P, Keshaviah A, Lahti-Domenici J, et al. A neural survival factor is a candidate oncogene in breast cancer. *Proc Natl Acad Sci U S A*. 2003;100:10931–6.
- Schitteck B, Hipfel R, Sauer B, Bauer J, Kalbacher H, Stevanovic S, et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. *Nat Immunol*. 2001;2:1133–7.
- Rieg S, Garbe C, Sauer B, Kalbacher H, Schitteck B. Dermcidin is constitutively produced by eccrine sweat glands and is not induced in epidermal cells under inflammatory skin conditions. *Br J Dermatol*. 2004;151:534–9.
- Minami Y, Uede K, Furukawa F, Sagawa K, Kimura A, Tsuji T. Cutaneous mixed tumors: an immunohistochemical study using two antibodies, G-81 and C8/144B. *J Dermatol Sci*. 2004;36:180–2.
- Minami Y, Uede K, Sagawa K, Kimura A, Tsuji T, Furukawa F. Immunohistochemical staining of cutaneous tumours with G-81, a monoclonal antibody to dermcidin. *Br J Dermatol*. 2004;151:165–9.
- Stewart GD, Lowrie AG, Riddick AC, Fearon KC, Habib FK, Ross JA. Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia. *Prostate*. 2007;67:1308–17.
- Stewart GD, Skipworth RJ, Pennington CJ, Ross JA, Fearon KCH, Baracos VE. Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines. *Br J Cancer*. 2008;99:126–32.
- Stewart GD, Skipworth RJ, Ross JA, Fearon K, Baracos VE. The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival. *Curr Opin Clin Nutr Metab Care*. 2008;11:208–13.
- Lowrie AG, Wigmore SJ, Wright DJ, Waddell ID, Ross JA. Dermcidin expression in hepatic cells improves survival without N-glycosylation, but requires asparagine residues. *Br J Cancer*. 2006;94:1663–71.
- Cunningham TJ, Jing H, Akerblom I, Morgan R, Fisher TS, Neveu M. Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells. *Exp Neurol*. 2002;177:32–9.
- Cunningham TJ, Hodge L, Speicher D, et al. Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin. *J Neurosci*. 1998;18:7047–60.

12. Rieg S, Seeber S, Steffen H, Humeny A, Kalbacher H, Stevanovic S, et al. Generation of multiple stable dermcidin-derived antimicrobial peptides in sweat of different body sites. *J Invest Dermatol*. 2006;126:354–65.
13. Steffen H, Rieg S, Wiedemann I, Kalbacher H, Eeg M, Sahl HG, et al. Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. *Antimicrob Agents Chemother*. 2006;50:2608–20.
14. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. *Br J Surg*. 2000;87:53–8.
15. Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). *Br J Cancer*. 1999;80:1734–7.
16. Lee Motoyama JP, Kim-Motoyama H, Kim P, Nakagawa H, Miyagawa K, Suzuki K. Identification of dermcidin in human gestational tissue and characterization of its proteolytic activity. *Biochem Biophys Res Commun*. 2007;357:828–33.
17. Sanghi S, Kumar R, Lumsden A, Dickinson D, Klepeis V, Trinkaus-Randall V, et al. cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland. *J Mol Biol*. 2001;310:127–39.
18. Ma P, Beck SL, Raab RW, McKown RL, Coffman GL, Utani A, et al. Heparanase deglycanation of syndecan-1 is required for binding of the epithelial-restricted prosecretory mitogen lacritin. *J Cell Biol*. 2006;174:1097–106.
19. Wang J, Wang N, Xie J, McKown RL, Raab RW, Ma P, et al. Restricted epithelial proliferation by lacritin via PKC alpha-dependent NFAT and mTOR pathways. *J Cell Biol*. 2006;174:689–700.
20. Weigelt B, Bosma AJ, Van't Veer LJ. Expression of a novel lacrimal gland gene lacritin in human breast tissues. *J Cancer Res Clin Oncol*. 2003;129:735–6.
21. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, et al. Regulation of in situ to invasive breast carcinoma transition. *Cancer Cell*. 2008;13:394–406.
22. Majczak G, Lilla S, Garay-Malpartida M, Marcovik J, Medrano FJ, de Nucci G, et al. Prediction and biochemical characterization of intrinsic disorder in the structure of proteolysis-inducing factor/dermcidin. *Genet Mol Res*. 2007;6:1000–11.
23. Li C, Wong WH. DNA-Chip Analyzer (dChip). In: Parmigiani G, Garrett ES, Irizarry R, Zeger SL, editors. *The analysis of gene expression data: methods and software*. New York: Springer; 2003. p. 120–41.
24. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. *Cancer Res*. 2008;68:9532–40.
25. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res*. 2002;30:e36.
26. Sagawa K, Kimura A, Saito Y, Inoue H, Yasuda S, Nosaka M, et al. Production and characterization of a monoclonal antibody for sweat-specific protein and its application for sweat identification. *Int J Legal Med*. 2003;117:90–5.
27. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER-2-overexpressing breast cancer cells. *Clin Cancer Res*. 2003;9:1274–83.
28. Logullo AF, Stiepcich MMA, Osório CABP, Nonogaki S, Pasini FS, Rocha RM, et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. *Histopathology*. 2011;58:617–25.
29. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell*. 2006;10:515–27.
30. Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. *Curr Opin Pharmacol*. 2007;7:392–7.
31. Muraoka-Cook RS, Feng SM, Strunk KE, Earp 3rd HS. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. *J Mammary Gland Biol Neoplasia*. 2008;13:235–46.
32. Muraoka-Cook RS, Sandahl M, Hunter D, Miraglia L, Earp 3rd HS. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. *Mol Endocrinol*. 2008;22:2307–3021.
33. Pawlowski V, Revillion F, Hebban M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. *Clin Cancer Res*. 2000;6:4217–25.
34. Revillion F, Lhotellier V, Hornez L, Bonnetterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. *Ann Oncol*. 2008;19:73–80.
35. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. *Nat Rev Mol Cell Biol*. 2006;7:505–16.
36. Monitto CL, Dong SM, Jen J, Sidransky D. Characterization of a human homologue of proteolysis inducing factor and its role in cancer cachexia. *Clin Cancer Res*. 2004;10:5862–9.
37. Song C, Weichbrodt C, Salnikov ES, Dynowski M, Forsberg BO, Bechinger B, et al. Crystal structure and functional mechanism of a human antimicrobial membrane channel. *Proc Natl Acad Sci U S A*. 2013;110(12):4586–91.
38. Moreira DF, Strauss B, Vannier E, Belizário JE. Genes up and down regulated by dermcidin in breast cancer: a microarray analysis. *Genet Mol Res*. 2007;7(4):925–32.
39. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. *Clin Cancer Res*. 2007;13:4909–19.
40. Wilhelm M, Schlegl J, Hahne H, Moghaddas Gholami A, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. *Nature*. 2014;509:582–7.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

